MicroRNAs (mRNA) are small, noncoding RNAs that help fine-tune gene expression, and when something goes awry with these tiny genetic pieces, cancer can develop. mRNA levels in the bloodstream can be tested and, Brady research has shown, are emerging as promising and highly precise biomarkers in the diagnosis and management of testicular cancer.

Urology resident Taibo Li, M.D., Ph.D., recently led a comprehensive study to investigate the landscape of microRNA expression in testicular cancer. In the study, published in Scientific Reports, investigators characterized the expression profile of 2,606 microRNAs across distinct subtypes of testicular cancer, in primary tumors as well as metastatic tumor sites in the lymph nodes. They discovered new candidate microRNA biomarkers capable of distinguishing among testicular cancer types.

“These exciting findings deepen our understanding of the mechanisms of testicular cancer formation,” says urologist Nirmish Singla, M.D., M.Sc. the study’s senior investigator. “We not only have uncovered novel candidate biomarkers, but potentially actionable targets to treat this disease.” This work was generously supported by the Ann and Chad Holliday, Jr. Discovery Fund.